- Spokane doctor’s kidney treatment will be tested in 11000-person study The Seattle Times
- Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial The Lancet
- ‘On par with the biggest breakthroughs in medicine’: Spokane doctor discovers new kidney disease treatment. An 11000-person study will start in 2024 The Spokesman Review
- Significant benefit seen in Phase III trial of experimental drug for kidney disease Medical Xpress
- Kidney Disease Drug Candidate Shows Broad Inhibition of Damaging Hormone Inside Precision Medicine
Read original article here